Skip to main content

Burn Scar

1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biomed
BiomedAustralia - Sydney
1 program
1
IP1 control creamPhase 2/31 trial
Active Trials
NCT06807021Recruiting70Est. Nov 2026
MTI
MTIUT - Salt Lake City
1 program
Shock waveN/A2 trials
Active Trials
NCT07510399Not Yet Recruiting70Est. Jun 2026
NCT07234305Completed80Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2025
2026
BiomedIP1 control cream
MTIShock wave
MTIShock wave

Clinical Trials (3)

Total enrollment: 220 patients across 3 trials

NCT06807021BiomedIP1 control cream

Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients

Start: Dec 2025Est. completion: Nov 202670 patients
Phase 2/3Recruiting
NCT07510399MTIShock wave

Effect of Extracorporeal Radial Shock Wave Ibuprofen Phonophoresis on Subacromial Space in Patients With Impingement Syndrome.

Start: Mar 2026Est. completion: Jun 202670 patients
N/ANot Yet Recruiting
NCT07234305MTIShock wave

Shock Wave Therapy Versus Conventional Physical Therapy for Partial- Thickness Forearm Burn Scars

Start: Oct 2025Est. completion: Feb 202680 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 220 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.